Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:conditionStudied |
obesity
overweight |
| gptkbp:controls |
placebo
|
| gptkbp:endDate |
2022
|
| https://www.w3.org/2000/01/rdf-schema#label |
SURMOUNT-1
|
| gptkbp:intervention |
gptkb:tirzepatide
|
| gptkbp:location |
multinational
|
| gptkbp:number |
NCT04184622
|
| gptkbp:participants |
2539
|
| gptkbp:period |
Phase 3
|
| gptkbp:publicationDate |
2022
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
percentage change in body weight from baseline
significant weight loss with tirzepatide compared to placebo |
| gptkbp:sponsor |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:startDate |
2019
|
| gptkbp:studyType |
gptkb:clinical_trial
|
| gptkbp:bfsParent |
gptkb:tirzepatide
|
| gptkbp:bfsLayer |
7
|